The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Antibody Patents after Centocor" on Wednesday, March 23, 2011 beginning at 2:00 PM (ET). The IPO webinar will examine how much descrioption is enough when it comes to written description for antibody patents as well as discuss the obviousness challenges antibody patents face since KSR. The speakers include Jack Brennan of Fish & Richardson, Nicholas Groombridge of Weil Gotshal, and Jane Gunnison of Ropes & Gray. The registration fee for the webinar is $120 (government and academic rates are available upon request). Those interested in registering for the webinar, can do so here.
Contributors
Juristat #4 Overall Rank
Contact the Docs
Foreign Correspondents
Recent Posts
- Astellas Pharma, Inc. v. Sandoz Inc. (Fed. Cir. 2024)
- Wisconsin Alumni Research Foundation v. Apple Inc. (Fed. Cir. 2024)
- Special Committee's Suspension Recommendation Adopted by Federal Circuit
- Natera, Inc. v. NeoGenomics Laboratories, Inc. (Fed. Cir. 2024)
- Andersen v. Stability AI: Defendants' Motion to Dismiss Narrows the Case, But Only Slightly
- Ryan LLC v. FTC: Texas Federal Court Strikes Down FTC's Prohibition on Non-Competes
- ABA Issues Formal Ethics Opinion on Use of Generative AI Tools
- United Therapeutics Corp. v. Liquidia Technologies Inc. (Fed. Cir. 2024)
- 91%: That is the Rate at Which the PTAB Affirms Examiner Section 101 Rejections
- Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc. (Fed. Cir. 2024)
Disclaimer
- "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat #8 Overall Rank
« Additional Opportunities for Pre- and Post-grant Review, and Brand New Patent Trial and Appeal Board in S. 23 | Main | BIO IPCC Spring Conference »
March 18, 2011
The comments to this entry are closed.
September 2024
Categories
- Artificial Intelligence (19)
- Best Mode (2)
- Biosimilars (247)
- Biotech/Pharma Business (175)
- Biotech/Pharma News (277)
- Board of Patent Appeals and Interferences (12)
- Claim Construction (104)
- Conferences & CLE's (2977)
- Copyright (4)
- Court Report (507)
- Damages (37)
- Definiteness (26)
- District Court (222)
- Double Patenting (37)
- Enablement (52)
- Federal Circuit (1016)
- Food and Drug Administration (109)
- Hatch-Waxman (93)
- Inequitable Conduct (52)
- Infringement - Contributory or Induced (28)
- Infringement - Literal or DOE (91)
- Injunction (34)
- International IP (297)
- Inventorship (17)
- Licensing (129)
- Media Commentary (71)
- Miscellaneous (168)
- News from Abroad (102)
- Novelty (73)
- Obviousness (232)
- Patent Exhaustion (3)
- Patent Legislation (312)
- Patent Litigation (217)
- Patent Office Rules & Procedures (827)
- Patent Profiles (104)
- Patent Prosecution (99)
- Patent Prosecution - International (26)
- Patent Research (4)
- Patent Trial and Appeal Board (368)
- Patentable Subject Matter (644)
- Personalized Medicine (5)
- Post-Grant Proceedings (158)
- PTAB Report (9)
- Study/Report (7)
- Supreme Court (262)
- Tools (5)
- Trade Secrets (13)
- Utility (4)
- Venue (11)
- Written Description (88)
Patent Resources
Patent Search
- Patent Search
Patent Blogs & Sites
- 717 Madison Place
- America-Israel Patent Law
- Anticipate This!
- BlawgIT
- Chicago IP Litigation Blog
- FedCircuitBlog
- Global Patent Quality
- Innovation Alliance
- Intellectual Property Watch
- IP Dragon
- IPcopy
- McCabe Ali LLP
- IPWatchdog.com
- Life Science IP
- Orange Book Blog
- Patent Blurb
- Patently-O
- Patentology
- Patents4Life
- Reexamination Center
- Intellepedia – IP News Center
- SPICY IP
Comments